and aging-related diseases, including Alzheimer's disease, announced final results from its Phase 2 study of TPN-101 in patients with amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD) related to hexanucleotide repeat...
Prolacta Bioscience®, the world's leading hospital provider of 100% human milk-based nutritional products, takes its obligation to the critically ill and premature infants it serves, and to the doctors providing them with care, extremely...
targeted immunotherapies for cancer, today announces positive treatment updates from its Phase 2 clinical trial, THIO-101, evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced...
medicines that harness IL-22 biology to drive improved outcomes for metabolic disease, announced positive data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of CK-0045, its lead lipidated IL-22 candidate, in healthy...
The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July 19, 2024. Bright Gene (Stock Code: 688166.SH) is...
the US to meet stricter timelines, and rapidly respond to challenges or threats. FLARE delivers the highest steady-state 14 MeV neutron source in the industry for radiation-hardened microelectronics and fusion component testing. It's also the...
Inc. (Nasdaq: NBIX) announced the launch of a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the #1 prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia and...
on validated targets in cancer and inflammatory diseases, announced that the first patient has been dosed in its Phase 1 clinical trial evaluating BTX-9341. An investigational oral and bifunctional degrader of cyclin-dependent kinase 4 (CDK4) and...
company developing biologic therapies for musculoskeletal ailments, announced initiation of enrollment for its Phase 1 clinical study of CYT-108. A recombinant variant of the alpha-2-macroglobulin blood serum protein, targeting proteases...
to emerging viral threats. Tiba Biotech's initial focus will be on developing a prototype RNAi-based therapeutic for H1N1 influenza that targets the highly conserved viral nucleoprotein and will be delivered via Tiba's RNABLTM platform. "We are...
for achieving functional cure in chronic hepatitis B (CHB) infection, announced that their investigational drug AHB-137 has received Breakthrough. Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of the National Medical Products...
Clarity AD study, Leqembi met its primary endpoint and all key secondary endpoints with statistically significant results.[1] In Hong Kong, 9.3% of people aged 70 years and older are living with dementia, and 32% of those aged 85 years and older,...
a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States (U.S.) with wet, or...
macular degeneration (nAMD), to the fourth single-dose group of 4mg and first multiple-dose group of 3mg in Phase 1 clinical trial. PMC-403 is a novel TIE2-activating antibody with the mechanism of stabilizing pathological and leaky blood vessels....
agreement, Biotest is expected to begin supplying Yimmugo® to Kedrion in Q4 2024, with a market launch planned for Q1 2025. The U.S. IG market is expected to grow by roughly 9% per year in the next eight years, representing an increasing patient...
(NHL) that arises from B-lymphocytes and is the second most common form of NHL accounting for 20-30% of all cases.2 About 15,000 people develop FL each year in the U.S.3 and it is considered incurable with current standard of care therapies.4...
results in multiple completed efficacy clinical trials. CalciMedica has completed a Phase 2b trial (called CARPO – NCT04681066) in AP with SIRS and a Phase 2b trial (called CARDEA – NCT04345614) in COVID pneumonia patients, continues to support the...
replication of these viruses. Currently, there is no treatment for dengue fever. The dengue virus has four serotypes (DENV-1, DENV-2, DENV-3, DENV-4), each with different IC50 values. The IC50 values for Zika, Chikungunya, and Yellow Fever viruses,...
honored by TIME Magazine, receiving high recognition for their proprietary technology with a Special Mention in TIME's 2021 Best Inventions. Led by CEO Chris Kanik, who is the season one winner of Gordon Ramsay's Food Stars on FOX, the Southern...
Rigaku Analytical Devices, a pioneer in developing handheld 1064 nm Raman analyzers, is pleased to announce distribution relationship Avantor, a leading provider of mission-critical products and services to the life sciences and advanced...